Transthyretin amyloidosis (ATTR) and its complications: optimizing management strategies
Cost: FreeView Offer chevron_right
Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. As TTR is a protein present in human serum, and its role is to transport thyroxine and retinol-binding proteins, it is vital for behavior, cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations. The familial variant of the disease is passed to offspring through autosomal dominant inheritance, whereas the wild type variant occurs independently of genetic mutations. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.
The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.
By the end of the session the participant will be able to:
- Describe the epidemiology of ATTR, including its subtypes.
- Compare and contrast invasive and non-invasive methods in the diagnosis of ATTR’s complications.
- Describe challenges in the management of ATTR, including under-diagnosis and challenges patients face in understanding the diagnosis and treatment of ATTR.
- Describe available and emerging therapies for ATTR and design an appropriate therapeutic plan including active patient involvement.